Results 131 to 140 of about 13,105 (210)

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no definitive cure is currently available. As a consequence, therapeutic efforts
Raffaele Epis, Gabriele Rovetta, Giulia Ferrari, Chiara Bonfanti, Giorgia Careccia, Graziella Messina   +5 more
wiley   +1 more source

Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option. [PDF]

Future Oncol
Collins SP, Maculaitis MC, Chakoian M.
europepmc   +1 more source

On‐site pilot‐scale advanced oxidation pretreatment of hospital wastewater: assessment of pharmaceuticals, pathogens, antibiotic resistance genes and acute ecotoxicity

Journal of Chemical Technology &Biotechnology, Volume 101, Issue 8, Page 1478-1491, August 2026.
Abstract BACKGROUND Hospital premises generate wastewater containing a wide spectrum of contaminants, such as pharmaceutically active compounds (PhACs), antibiotic resistance genes (ARGs) and pathogenic microorganisms, whilst plenty of them are classified under the antibiotic resistant bacteria (ΑRΒ) category.
Andreas Kaliakatsos, Iosifina Gounaki, Spyros Dokianakis, Georgios Gkotsis, Maria‐Christina Nika, Eleni Aleiferi, Athanasios S Stasinakis, Nikos Katsarakis, Nikolaos S Thomaidis, Thrassyvoulos Manios, Michalis S Fountoulakis, Danae Venieri   +11 more
wiley   +1 more source

Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System. [PDF]

Pharmaceuticals (Basel)
Yajima A, Uesawa Y.
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Pharmaceutical Utilization Review: A Five-Year Time Trend Analysis of the Pharmaceutical Market in Iran. [PDF]

Iran J Pharm Res
Nemati M, Fatemi B, Soleymani F, Seyedifar M, Zali D, Shahali Z, Ranjbaran H.   +6 more
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, Volume 20, Issue 7, Page 1667-1693, July 2026.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Chemobrain as a Neuroimmune Syndrome: Mechanisms, Modifiers, and Emerging Multi-Target Therapeutic Strategies. [PDF]

Molecules
Carnemolla F, Singh SK, Ceccherini L, Taddei N, Bucciantini M, Leri M.   +5 more
europepmc   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, Volume 16, Issue 7, Page 1358-1369, July 2026.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis. [PDF]

Cancer Rep (Hoboken)
Seyoum Tadesse D, Tekletsadik K, Begashaw B, Shewasinad Yehualashet A, Mekonnen Ali A, Ayenew KD.   +5 more
europepmc   +1 more source